You just read:

Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

News provided by

Mallinckrodt Pharmaceuticals

Feb 20, 2019, 06:55 ET